Research Article

p21-Activated Kinase 4 Promotes Intimal Hyperplasia and Vascular Smooth Muscle Cells Proliferation during Superficial Femoral Artery Restenosis after Angioplasty

Liangxi Yuan, Xianli Duan, Jian Dong, Qingsheng Lu, Jian Zhou, Zhiqing Zhao, Junmin Bao, and Zaiping Jing

Department of Vascular Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China

Correspondence should be addressed to Junmin Bao; xueguankyb@163.com and Zaiping Jing; xueguankyy@163.com

Received 28 December 2016; Accepted 3 May 2017; Published 19 June 2017

The aim of this study is to explore the function of p21-activated kinase 4 (PAK4) in intimal hyperplasia (IH) and vascular smooth muscle cells (VSMCs) proliferation. We choose vascular samples from patients undergoing angioplasty in superficial femoral artery (SFA) as the experimental group and vascular samples from donors without clinical SFA restenosis as the control group, respectively. We draw from the results that both levels of mRNA and protein of PAK4 in the experimental group increased dramatically compared with the control group. IH arose from angioplasty of SFA. Moreover, overexpression of PAK4 dramatically contributed to cell proliferation of VSMCs and promoted cell cycle progression from G0/G1 phase ($71.12\pm0.69\%$ versus $58.77\pm0.77\%, P<0.001$) into S phase ($23.99\pm0.21\%$ versus $31.35\pm0.33\%, P<0.001$). Besides, PAK4 downregulated the level of p21 and enhanced the activity of Akt as well. And we conclude that PAK4 acts as a regulator of cell cycle progression of VSMC by mediating Akt signaling and controlling p21 levels, which further modulate IH and VSMCs’ proliferation.

1. Introduction

Advanced angioplasty and stenting technology are two main therapeutic methods for treating cardiovascular disease. Although therapeutic percutaneous interventions have shown some good therapeutic efficacy of diverse vascular beds, such as the abdominal aorta and the iliac arteries [1, 2], the superficial femoral artery (SFA) restenosis and occlusion is of frequent occurrence after these interventions [3]. Additionally, it has been reported that vascular restenosis, as a critical complication after these procedures, is secondary to intimal hyperplasia (IH) [4]. Proliferation of VSMCs is a hallmark of the early pathologic appearance of IH [5, 6]. Given this, inhibition of VSMCs proliferation is the key to prevention and treatment of IH.

The p21-activated kinases (PAKs) are a family of serine/threonine kinases that are major effector proteins for the Rho GTPases Cdc42 and Rac, which are important for cell morphology and cytoskeletal reorganization [7, 8], as well as various cell processes including proliferation, migration, and survival [9–11]. Among them, p21-activated kinase 4 (PAK4) is the most unique and profoundly studied member. PAK4 is expressed at low levels in the majority of normal adult tissues and accumulating documents have reported that the aberrant expression of PAK4 is closely related to the diverse cancers, such as glioma, breast cancer, colon and gastric cancers, and prostate cancer [12–14]. Moreover, high expression of PAK4 is closely associated with cell proliferation, migration, invasion of ovarian cancer cell, and poor prognosis in patients [15]. Of significance, it has been reported that PAK4 plays an important role in the cell cycle through regulating the level of p21, a key member of the cyclin-dependent kinase- (CDK-) inhibitory protein family, in fibroblasts [16]. Additionally, PAK4 is highly expressed in embryonic stage, and knock-out of PAK4 would result in embryonic lethality, accompanied by anomalies in the heart and placenta and defects in vascular system [17, 18]. However, till date, there is no documented evidence of its pathological significance in VSMCs proliferation.
In the present study, we investigate whether PAK4 is involved in vascular restenosis using vascular samples from patients that underwent angioplasty of SFA and cell proliferation of VSMCs.

2. Materials and Methods

2.1. Ethics Statement. All procedures involving the use of human tissue were approved by the Ethics Committee of Changhai Hospital Second Military Medicine University, according to all ethical principles including the World Medical Association Declaration of Helsinki and the local legislation. All of the experiments were undertaken with the understanding and written consent of each subject according to the abovementioned principles.

2.2. Clinical Data and Tissue Specimens. The SFA samples were collected from 2014 to 2015 at Changhai Hospital Second Military Medicine University (experimental group, patients underwent percutaneous transluminal angioplasty (PTA) treatment of SFA, \(n = 3\); control group, donors without clinical SFA restenosis, \(n = 3\)). Patients were treated in the standard manner of our practice. The three patients showed clinical restenosis and lower-limb necrosis was after postprocedure 10, 13, and 15 months, respectively. The SFA restenosis samples were harvested through amputation above the knee. The control SFA samples were obtained from the corresponding region of donors without clinical SFA restenosis. The SFA samples were promptly washed with PBS and resected longitudinally by the surgeon. Parts of the samples were stored immediately in –80°C for qRT-PCR assay and western blot analysis. The remaining samples were embedded with paraffin and prepared for further H&E staining. The inclusion criteria for the experimental participants were as follows: (1) CT angiography (CTA) showing that SFA restenosis occurred after the PTA treatment; (2) being willing to participate in the study. Exclusion criteria included CT angiography (CTA) showing SFA restenosis after the other surgery besides PFA treatment.

2.3. Cell Culture. Human vascular smooth muscle cell line T/G HA VSMC (ATCC® number: CRL-1999™) was purchased from American Type Culture Collection. Cells were cultured in Ham's F12K medium with 2 mM L-glutamine supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified incubator with 5% CO₂. Then, cells were trypsinized, transferred to 10 cm tissue culture dishes, and cultured to subconfluence. Cells at passages 4–8 were used. Cells overexpressing PAK4 were obtained by transfection with PAK4 ORF expression clone vector, using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. For further experiments, cells were cultured in 6-well or 96-well plates with serum-free medium for 24 h.

2.4. Quantitative Real-Time PCR. Total RNA was isolated using TRIzol reagent (Invitrogen) according to the manufacturer's protocol. For the reverse transcription reaction, TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) was applied. qRT-PCR was carried out in 7500 Fast Real-Time PCR System (Applied Biosystem) by using SYBR Green Universal Master Mix (Roche). Briefly, the following PCR program was performed: 50°C for 2 min and 95°C for 3 min, followed by 40 cycles for 15 s at 95°C and 56°C for 45 s. The sequence information is as follows: PAK4, forward primer: 5'-TCCCCCTGAGCCATTGTTG-3' and reverse primer: 5'-TG ACCTGCTTCCTCCATCA-3'; β-actin, forward primer: 5'-CTGCGCA TGGACCCTTC-3' and reverse primer: 5'-GCTTTGATCTCTCATGGTGCTAGG-3'. Mature PAK4 mRNA levels in cells were measured by 2-ΔΔCt method, with β-actin as an internal control.

2.5. Cell Proliferation Assay. Cell proliferation of VSMCs was detected via cell count technique. In brief, cells were seeded in 96-well plates with a density of 1 × 10⁴ cells/mL and incubated for 24, 48, and 72 h. Then, cell proliferation was assessed by direct cell count with a Coulter Counter. The experiments were performed three times.

2.6. BrdU Incorporation Assay. The viability of the VSMCs was determined by 5-Bromo-2-deoxyuridine (BrdU) assay according to the manufacturer’s instructions. Cells transfected with PAK4 or control vectors were seeded in sterile 96-well culture plates at a density of 2 × 10⁵ cells per well with serum-free medium and incubated for 48 or 72 h. Then, cells were incubated in medium containing a final concentration of 10 μM BrdU for 2h. Subsequently cells were washed and fixed with 2% paraformaldehyde solution for 25 min at room temperature and then washed three times with PBS to discard the culture medium. After observation, pictures were taken randomly in diverse views under a fluorescent inverted microscope.

2.7. Cell Cycle Assay. Flow cytometry was conducted to analyze cell cycle. The cells were collected, trypsinized, and fixed with 75% methanol at –20°C overnight and then washed in PBS three times and incubated with PBS containing 10 ng/mL propidium iodide (PI), 100 μg/mL RNase A, and 0.2% Triton X-100 for 30 min at 4°C in the dark. DNA content was monitored using a cell sorter (FACScalibur, BD).

2.8. Western Blot. The PAK4 protein levels of VSMCs and clinical tissues were assayed by western blot technology. The cells were grown in 6-well culture dishes to 70% confluence. Cells and tissues were lysed with RIPA buffer. After 15 min incubation, lysates were centrifuged at 12,000 g for 15 min, and the collected protein was loaded onto 10% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) and transferred onto polyvinyl difluoride (PVDF) membrane. The membranes were blocked with skimmed milk powder in Tris-buffered saline and then incubated with primary anti-PAK4 (1:500), anti-p21 (1:400), anti-p-Akt (1:1000), anti-Akt (1:300), and anti-β-actin (1:200) at 4°C overnight, followed by incubation with horseradish peroxidase-conjugated anti-rabbit secondary antibody (1:5000). The bands were visualized with the enhanced chemiluminescence plus system (ThermoFisher Scientific).
3. Results

3.1. PAK4 Expression in Human Vascular Walls with IH. The degree of IH was evaluated morphologically using H&E staining. As shown in Figure 1(a), the intima layer was dramatically thickened in experimental group compared with the control group. To define the clinical functional role of PAK4, we detected the mRNA and protein expression levels of PAK4 in tissues with IH that arose from angioplasty. qRT-PCR indicated that, compared with the control samples, IH significantly increased the mRNA level of PAK4 (Figure 1(b)). Consistent with these, the western blot results showed that the expression of PAK4 protein was remarkably unregulated by IH (Figure 1(c)).

3.2. PAK4 Facilitates Vascular Smooth Muscle Cells’ Proliferation. To gain insight into the pathobiological involvement of PAK4 in IH, the VSMCs of PAK4 overexpression were constructed. We identified the efficiency of transfection with
Figure 2: PAK4 promotes vascular smooth muscle cells' (VSMCs) proliferation. (a) qRT-PCR analysis of PAK4 mRNA levels in OE-PAK4 VSMCs and the control group. (b) Western blot analysis of PAK4 protein levels in OE-PAK4 VSMCs and the control group. (c) Cell growth detected by cell count technique. (d) Cell proliferation was detected by BrdU incorporation assay (magnification ×200). BrdU (green fluorescence) and DAPI (blue fluorescence). The stained images were digitally merged. (OE-PAK4: overexpression of PAK4 VSMCs group. Con: control VSMCs group; n = 3, data are means ± SD, * P < 0.05, ** P < 0.001 versus Con).

qRT-PCR and western blot. As a result, PAK4 mRNA and protein levels were significantly higher in VSMCs of PAK4 overexpression than the control cell line transfected with mock-vehicle (Figures 2(a) and 2(b)). Further, cell count technique and BrdU incorporation assay were performed to detect cell proliferation. As shown in Figure 2(c), PAK4 overexpression in VSMCs resulted in faster growth than that in control group, especially when cells were incubated for 48 h (42.80% versus 30.46%, P < 0.001). Similarly, in BrdU assay, PAK4 overexpression in VSMCs obviously
accelerated cell proliferation at 48 h (Figure 2(d)). These data indicated that PAK4 could facilitate the proliferation of VSMCs.

3.3. PAK4 Promotes Vascular Smooth Muscle Cells’ Cycle Progression. The effects of PAK4 on cell cycle progression were also analyzed. Flow cytometry analysis revealed that overexpression of PAK4 obviously increased the number of VSMCs in the G2/M phase and S phase (4.88 ± 0.12% versus 9.88 ± 0.06%, P < 0.001; 23.99 ± 0.21% versus 31.35 ± 0.33%, P < 0.001) (Figures 3(a) and 3(b)). The percentage of cells in G0/G1 phase decreased from 71.12% to 58.77% after PAK4 overexpressed in VSMCs (Figures 3(a) and 3(b)). This data suggested that PAK4 might promote the progression

Figure 3: PAK4 regulates vascular smooth muscle cells cycle progression. (a) PAK4 expression promotes VSMCs in the S phase of the cell cycle analyzed by flow cytometry (peak image). (b) PAK4 expression promotes VSMCs in the S phase of the cell cycle analyzed by flow cytometry (bar image). OE-PAK4: overexpression of PAK4 VSMCs group. Con: control VSMCs group.
Table 1: Patient characteristics of the 6 samples.

| Demographics | Control group | Experimental group |
|--------------|---------------|-------------------|
| Gender       |               |                   |
| Male         | 123           | Male              |
| Female       | 76            | Female            |
| Age (year)   | 76            | 79                |
| Hypertension | +             | +                 |
| Coronary disease | -       | +                 |
| Diabetes     | -             | -                 |
| Atrial fibrillation | -   | -                 |
| Chronic renal insufficiency | - | -                 |
| Hyperlipemia | -             | +                 |
| Cerebral infarction | - | +                 |
| Smoking history | +       | -                 |

| Demographics | Control group | Experimental group |
|--------------|---------------|-------------------|
| Gender       |               |                   |
| Male         | 4             | Male              |
| Female       | 56            | Female            |
| Age (year)   | 79            | 74                |
| Hypertension | +             | +                 |
| Coronary disease | +       | +                 |
| Diabetes     | -             | -                 |
| Atrial fibrillation | -   | -                 |
| Chronic renal insufficiency | - | -                 |
| Hyperlipemia | -             | +                 |
| Cerebral infarction | - | +                 |
| Smoking history | -       | -                 |

of cell cycle from G0/G1 phase into S phase, which further contributed to the proliferation of VSMCs.

3.4. PAK4 Modulates p21 Expression and Akt Activation. To define the potential mechanism by which PAK4 signaling confers regulating cell cycle progression, we investigated the expression level of several putative cell cycle-related factors in VSMCs. In the overexpressing PAK4 group and control group, we detected the protein expression levels of p21, p-Akt, and Akt by using western blot analysis. As the results showed, the level of p21 protein was dramatically low in PAK4 overexpressed VSMCs group compared to the control cell line (Figure 4(a)). At the same time, overexpression of PAK4 notably increased the phosphorylation of Akt, while it had no effect on total protein levels of Akt. The data together indicated that PAK4 might mediate cell cycle progression through regulating the expression of p21 and the activation of Akt, further contributing to VSMC proliferation (Figure 4(b)).

4. Discussion

Percutaneous transluminal angioplasty (PTA) and stent implantation have become a top option of therapeutic schedule in atherosclerotic diseases, which is mainly manifested by peripheral arterial occlusive disease. However, PTA contributes to the occurrence of restenosis, especially in the SFA, which would dramatically decrease the efficacy of treatment [19]. Thus, it is of great importance to inhibit post-PTA restenosis. It has been widely accepted that the VSMCs proliferation was the pathological basis of IH, further resulting in vascular stenosis [20, 21].

The PAK proteins family was involved in diverse cellular activities, which was classified into group I (PAK1-3) and group II (PAK4-6), based on the domain organization and regulatory properties [22]. PAK4, the prototype of group II PAKs, has been indicated to be involved in a variety of cellular processes, including cell proliferation, cell mobility, and cell cycle regulation [16, 23]. Cell cyclin-dependent kinase inhibitor p21 plays an important role in suppressing cell cycle progression. Previous report indicated that knockdown of PAK4 obviously prohibited breast cancer cell proliferation [22]. However, the role of PAK4 in VSMCs proliferation has not been explored. Here, clinical studies reveal that IH results in an enhancement of PAK4 expression. Therefore, it is not surprising that PAK4 has effect on cell proliferation in VSMCs. In our study, VSMCs proliferation was increased with the overexpression of PAK4, which confirmed the speculation.

Improper regulation of cell cycle could be the vital factor of aberrant cell proliferation. p21, a member of CDK-inhibitory protein family, suppresses cell cycle process through the Ras-Raf-MEK-ERK signaling pathway [24, 25]. p21 is a short-lived protein, of which the level is modulated by ubiquitin-independent proteasome degradation process [26]. Diverse signaling pathways could contribute to the alteration of p21 level via different mechanism. Importantly, it has been documented that PAK4 plays a significant role in the initiation of cell cycle via regulating the cell cycle regulatory protein p21 [16]. In the present study, we demonstrated that overexpression of PAK4 arrested the cell cycle in S phase by flow cytometer. And further western blot results revealed that the expression of p21 protein was dramatically downregulated with the overexpression of PAK4 in VSMCs. Our study reported the integrated roles for PAK4 and p21 in VSMCs, which are of great importance in VSMCs proliferation and the development of restenosis.

It is well established that Akt plays an important role in regulating cell cycle progression and cell survival by targeting at diverse downstream targets [27]. Moreover, in VSMCs, the Akt signal was proved to be closely related to controlling VSMCs proliferation, at least partly, through modulating p21 level [28]. Besides, a relationship between Akt and PAK4 has also been previously demonstrated. PAK4 has been shown to be controlled by microRNA-433 and subsequently attenuates Akt signaling, resulting in regulating the proliferation of hepatocellular carcinoma (HCC) cells. Following these data, we speculated that PAK4 might have some effect on p21 expression via regulating the activity of Akt signaling in VSMCs. This notion was validated by our findings that overexpression of PAK4 in VSMCs remarkably decreased the level of p21 and enhanced the activation of Akt simultaneously and
Figure 4: The mechanism of PAK4 modulating VSMCs proliferation. (a) Western blot analysis of p21, p-Akt, and Akt protein levels in OE-PAK4 VSMCs and control group. The protein expression levels were normalized to \( \beta \)-actin. *\( P < 0.05 \). (b) A model of PAK4 mediating VSMCs proliferation. PAK4 expression induces the activation of Akt signaling, which further attenuates the level of p21. The decreased p21 level promotes G0/S transition in cell cycle progression and then contributes to VSMCs proliferation (n = 3).

5. Conclusions

In conclusion, we provided the direct evidence that PAK4 was involved in IH triggered by angioplasty with clinical data. The results demonstrated that PAK4 mediated IH via promoting cell proliferation of VSMCs. Further, we sought to verify the underlying mechanism of this effect, and the data suggested that PAK4 increased VSMCs proliferation through activating the Akt signaling and downregulating the expression of p21 protein, further resulting in G0/S phase transition of cell cycle progression. These findings contribute to the clarification of the crucial role of PAK4 in IH and might provide potential therapeutic targets for restenosis.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors are grateful to all participants for their participation in this investigation. This work was supported by the National Natural Science Foundation of China (no. 81500390 and no. 81370441).
References

[1] N. J. Aranson and M. T. Watkins, "Percutaneous interventions in aortic disease," *Circulation*, vol. 131, no. 14, pp. 1291–1299, 2015.

[2] T. M. Sullivan, M. B. Childs, J. M. Bacharach, B. H. Gray, M. R. Piedmonte, and T. Stanson, "Percutaneous transluminal angioplasty and primary stenting of the iliac arteries in 288 patients," *Journal of Vascular Surgery*, vol. 25, no. 5, pp. 829–839, 1997.

[3] B. H. Gray, T. M. Sullivan, M. B. Childs, J. R. Young, and J. W. Olin, "High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty," *Journal of Vascular Surgery*, vol. 25, no. 1, pp. 74–83, 1997.

[4] W. S. Weintraub, ""The pathophysiology and burden of restenosis," *The American Journal of Cardiology*, vol. 100, no. 5, pp. S3–S9, 2007.

[5] S.-Y. Kim, N. H. Jeoung, C. J. Oh et al., "Activation of NAD(P)H:quinone oxidoreductase 1 prevents arterial restenosis by suppressing vascular smooth muscle cell proliferation," *Circulation Research*, vol. 104, no. 7, pp. 842–850, 2009.

[6] F. Vogt, A. Zernecke, M. Beckner et al., "Blockade of angio-associated migratory cell protein inhibits smooth muscle cell migration and neointima formation in accelerated atherosclerosis," *Journal of the American College of Cardiology*, vol. 52, no. 4, pp. 302–311, 2008.

[7] J. Zhu, O. Attias, L. Aoudjit, R. Jiang, H. Kawachi, and T. Takano, "p21-activated kinases regulate actin remodeling in glomerular podocytes," *American Journal of Physiology—Renal Physiology*, vol. 298, no. 4, pp. F951–F961, 2010.

[8] C. K. Rane and A. Minden, "p21 activated kinases: structure, regulation, and functions," *Small GTPases*, vol. 5, Article ID e28003, 2014.

[9] D. Kim, C. Choi, C. Lee et al., "Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain," *Experimental & Molecular Medicine*, vol. 48, no. 4, p. e229, 2016.

[10] Z. Li, H. Zhang, L. Lundin et al., "p21-activated kinase 4 phosphorylation of integrin β3 Ser-759 and Ser-762 regulates cell migration," *Journal of Biological Chemistry*, vol. 285, no. 31, pp. 23699–23710, 2010.

[11] Y. Liu, H. Xiao, Y. Tian et al., "The Pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice," *Molecular Cancer Research*, vol. 6, no. 7, pp. 1215–1224, 2008.

[12] T. Ahmed, K. Shea, J. R. W. Masters, G. E. Jones, and C. M. Wells, "A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF," *Cellular Signalling*, vol. 20, no. 7, pp. 1320–1328, 2008.

[13] D. Kesnakurti, C. Chetty, D. Rajasekhar Maddirela, M. Gujrati, and J. S. Rao, "Functional cooperativity by direct interaction between PAK4 and MMP-2 in the regulation of anoikis resistance, migration and invasion in glioma," *Cell Death & Disease*, vol. 3, article e445, 2012.

[14] H. J. Zhang, M. K. Siu, M. C. Yeung et al., "Overexpressed PAK4 promotes proliferation, migration and invasion of choriocarcinoma," *Carcinogenesis*, vol. 32, no. 5, pp. 765–771, 2011.

[15] M. K. Y. Siu, H. Y. Chan, D. S. H. Kong et al., "p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 43, pp. 18622–18627, 2010.

[16] T. Nekrasova and A. Minden, "PAK4 is required for regulation of the cell-cycle regulatory protein p21, and for control of cell-cycle progression," *Journal of Cellular Biochemistry*, vol. 112, no. 7, pp. 1795–1806, 2011.

[17] J. Qu, X. Li, B. G. Novitch et al., "PAK4 kinase is essential for embryonic viability and for proper neuronal development," *Molecular and Cellular Biology*, vol. 23, no. 20, pp. 7122–7133, 2003.

[18] Y. Tian, L. Lei, M. Cammarano, T. Nekrasova, and A. Minden, "Essential role for the Pak4 protein kinase in extracellular matrix gene expression and tissue development and vessel formation," *Mechanisms of Development*, vol. 126, no. 8–9, pp. 710–720, 2009.

[19] Y. H. Li, Q. X. Wang, J. W. Zhou et al., "Effects of rosuvastatin on expression of angiotensin-converting enzyme 2 after vascular balloon injury in rats," *Journal of Geriatric Cardiology*, vol. 10, no. 2, pp. 151–158, 2013.

[20] A. J. Lusis, "Atherosclerosis," *Nature*, vol. 407, no. 6801, pp. 233–241, 2000.

[21] Z. H. Mnjoyan, D. Doan, J. L. Brandon et al., ""The critical role of the intrinsic VSMC proliferation and death programs in injury-induced neointimal hyperplasia," *American Journal of Physiology—Heart and Circulatory Physiology*, vol. 294, no. 5, pp. H2276–H2284, 2008.

[22] R. Kumar, A. E. Gururaj, and C. J. Barnes, "p21-activated kinases in cancer," *Nature Reviews Cancer*, vol. 6, no. 6, pp. 459–471, 2006.

[23] A. E. Dart and C. M. Wells, "p21-activated kinase 4—not just one of the PAK," *European Journal of Cell Biology*, vol. 92, no. 4-5, pp. 129–138, 2013.

[24] M. E. Bottazzi, X. Zhu, R. M. Böhm er, and R. K. Assoian, ""Regulation of p21(cip1) expression by growth factors and the extracellular matrix reveals a role for transient ERK activity in GI phase," *Journal of Cell Biology*, vol. 146, no. 6, pp. 1255–1264, 1999.

[25] M. F. Olson, H. F. Paterson, and C. J. Marshall, "Signals from Ras and Rho GTPases interact to regulate expression of p21(Waf1/Cip1)," *Nature*, vol. 394, no. 6690, pp. 295–299, 1998.

[26] X. Chen, Y. Chi, A. Bloecher, R. Aebbersold, B. E. Clurman, and J. M. Roberts, "N-acetylation and ubiquitin-independent proteasomal degradation of p21 Cip1," *Molecular Cell*, vol. 16, no. 5, pp. 839–847, 2004.

[27] J. R. Testa and A. Bellacosa, "AKT plays a central role in tumorigenesis," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 20, pp. 10983–10985, 2001.

[28] E. Stabile, Y. F. Zhou, M. Saji et al., "Akt Controls Vascular Smooth Muscle Cell Proliferation in Vitro and in Vivo by Delaying G1/S Exit," *Circulation Research*, vol. 93, no. 11, pp. 1059–1065, 2003.